News & Updates
Filter by Specialty:
Show Multimedia Only

JAK inhibitor a new hope for new-onset T1D?
02 Oct 2025
byAudrey Abella
The 2-year outcomes from the phase II BANDIT* trial confirm the potential of the Janus kinase (JAK) inhibitor baricitinib for the treatment of new-onset type 1 diabetes (T1D).
JAK inhibitor a new hope for new-onset T1D?
02 Oct 2025
Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
01 Oct 2025
byStephen Padilla
Reducing the dose of trastuzumab deruxtecan (T-DXd) does not have any significant effect on real-world (rw) progression-free survival (PFS) or treatment-related toxicities among patients with metastatic breast cancer (MBC), as shown in a Singapore study.
Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
01 Oct 2025
Long COVID symptoms may persist 3 years post-infection
01 Oct 2025
byAudrey Abella
One in five COVID-19 survivors experiences at least one unresolved symptom 3 years after the initial infection, a systematic review and meta-analysis reports.